Separate prescription and monitoring decisions

Boston Medical Group review

Boston Medical Group has a current catalogue spanning NAD+, sermorelin and weight care, with separately priced plans. I would evaluate one service at a time. Its consultations and messaging may help coordinate care, but a broad menu does not establish a complete testing programme, interchangeable treatment evidence or improved healthy lifespan.

A useful next step?

Consider the purpose, the care relationship and the full commitment.

Visit Boston Medical GroupOfficial provider website. No affiliate relationship is currently listed.

A reason to consider it

Readers comparing one clinician-reviewed service who will verify the actual preparation, monitoring needs and complete selected commitment.

  • Dedicated current pages identify NAD+, sermorelin and GLP offers separately.
  • Selected prices and renewal intervals are visible.
  • The marketplace explains pharmacy choice and independent clinical roles.

What deserves scrutiny

People choosing a broad anti-aging bundle on the assumption that every test, outcome or preparation is established by the catalogue.

  • General monitoring and educational descriptions do not establish a full prepaid lab panel.
  • Actual formulation, supplied quantity and dispensing schedule remain important questions.
  • GLP-specific shipping statements conflict with the general policy.
In this review

Start with the clinical purpose, then the product

The current store lists a NAD+ injectable plan from $199 for one month and a sermorelin page with selected $195 one-month and $575 three-month options. A separate GLP page provides semaglutide and tirzepatide plans. Those are distinct preparations and clinical questions, not one established longevity intervention. I would ask what meaningful outcome the clinician expects and what evidence supports that particular prescription. [1] [2] [3]

The pages do not fully identify every ingredient, concentration, vial volume, count or individual supplied interval. Product imagery is expressly not the actual dispensing label. A broad selection of services does not establish that combining them improves healthy lifespan, and the NAD injectable offer is not an included IV appointment. Keep the actual treatment and care setting clear. [1] [2] [3]

Use the full term and the actual supply

Sermorelin’s $575 selection renews every three months, while its $195 option and the NAD+ plan renew monthly. GLP semaglutide totals are $190/$399/$714/$1,188 for one/three/six/twelve months; tirzepatide totals are $239/$589/$1,074/$1,788. Their renewal intervals change with the selection. A low monthly equivalent does not make the longer term a flexible monthly bill. [1] [2] [3]

FAQ says medication is billed when shipped. The GLP page keeps a four-week medication label on longer terms, so clarify shipment cadence and actual supplied quantity. General inclusion of consultations, supplies and messaging does not establish an included complete lab panel, private dietitian appointments or fixed live follow-up. Compare confirmed testing and care costs separately. [3] [4]

The dispensing relationship needs its own check

The marketplace says independent clinicians make treatment decisions and pharmacies dispense; it does not itself treat or manufacture the medicine. FAQ names Manifest Pharmacy and RX Compounding Store as possible dispensers and permits a local-pharmacy request without guaranteeing its price. Those statements do not independently verify the actual clinician, facility, license or batch assigned to an individual. [4] [6] [7]

The GLP product instructs refrigeration, while the general refund policy says refrigerated products are not currently shipped. Obtain current, preparation-specific shipping instructions. FDA recommends not using injectable GLP-1 medicine arriving warm or inadequately refrigerated; do not transfer a generic assurance across products. Compounded drugs are not FDA-approved finished medicines. [3] [5] [8]

Separate the renewal decision from the final-sale rule

Patients are described as being contacted before refill and billing, with account cancellation before shipment. The prescription policy makes sales final after payment has been charged and the parcel handed to the carrier. Obtain the actual next charge and order status; no universal advance-notice period, partial-term cash refund or physician-nonapproval refund timetable is clearly established by these public pages. [4] [5]

The policy says to report damage and describes reshipping lost orders after carrier-location efforts. That is not a general guarantee of a cash remedy for every delay or disappointing result. My assessment would depend on one defined care need, a complete preparation and a monitoring and financial agreement the reader can evaluate before the next renewal. [5]

Understanding the cost

NAD+ one-month injectable plan from $199, monthly renewal. Sermorelin selected one/three-month totals $195/$575, matching renewal intervals. GLP selected totals vary by medicine and one/three/six/twelve-month term; confirm the full preparation, billing and shipment arrangement for the chosen service. [1] [2] [3]

Build your cost estimate

Sources

  1. Boston Medical Group: NAD+ injectable, one-month supply and renewal
  2. Boston Medical Group: selected one- and three-month sermorelin plans
  3. Boston Medical Group: selected semaglutide and tirzepatide plans
  4. Boston Medical Group: billing, pharmacy, state and cancellation answers
  5. Boston Medical Group: prescription returns, carrier handoff and loss policy
  6. Boston Medical Group: served terms last updated October 26, 2023
  7. Boston Medical Group: current product scope and marketplace role
  8. FDA: concerns with unapproved GLP-1 drugs, shipping and salt forms

This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.

Affiliate partner

Before you go

Explore this option
Continue to your original choiceWe may earn a commission if you choose our partner. These services may differ in products, fees and clinical access.